Refine my results
Document type
Institution
Specific Collection
Language
- English (2)
Author
- Catapano, Carlo V. (2)
- Civenni, Gianluca (2)
- Alimonti, Andrea (1)
- Brambilla, Lara (1)
- Carbone, Giuseppina M. (1)
- D'Antuono, Rocco (1)
- Di Mitri, Diletta (1)
- Garcia-Escudero, Ramon (1)
- Genini, Davide (1)
- Grassi, Fabio (1)
- Guccini, Ilaria (1)
- Jarrossay, David (1)
- Kalathur, Madhuri (1)
- Laurini, Erik (1)
- Levy, David E. (1)
- Marini, Camilla (1)
- Merulla, Jessica (1)
- Montani, Erica (1)
- Pandit, Shusil (1)
- Pandolfi, Pier Paolo (1)
- Perez, Laurent (1)
- Pinton, Sandra (1)
- Pricl, Sabrina (1)
- Proietti, Michele (1)
- Revandkar, Ajinkya (1)
- Sarti, Manuela (1)
- Scanziani, Eugenio (1)
- Toso, Alberto (1)
- Zhang, Jiangwen (1) More Less
Keyword
- Mitochondria (1)
- OPB-51602 (1)
- Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However (1)
- STAT3 (1)
- Small-molecule inhibitor (1)
- Synthetic lethality (1)
- activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in Pten-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2 (1)
- in Pten-null senescent tumors (1)
- providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly (1)
- these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments. (1)
- this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein (1)
- treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in Pten-null tumors. Altogether (1)
- we report that (1) More Less